Invizyne Technologies (NASDAQ:IZTC) versus C4 Therapeutics (NASDAQ:CCCC) Head to Head Analysis

Invizyne Technologies (NASDAQ:IZTC) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Earnings and Valuation

This table compares Invizyne Technologies and C4 Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
C4 Therapeutics	$35.58 million	2.47	-$132.49 million	($1.51)	-0.82

Invizyne Technologies has higher earnings, but lower revenue than C4 Therapeutics.

Profitability

This table compares Invizyne Technologies and C4 Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
C4 Therapeutics	-313.35%	-42.45%	-27.55%

Insider & Institutional Ownership

78.8% of C4 Therapeutics shares are held by institutional investors. 8.6% of C4 Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings for Invizyne Technologies and C4 Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0	0	0	0	0.00
C4 Therapeutics	0	2	3	0	2.60

C4 Therapeutics has a consensus target price of $12.50, indicating a potential upside of 908.06%. Given C4 Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe C4 Therapeutics is more favorable than Invizyne Technologies.

Summary

C4 Therapeutics beats Invizyne Technologies on 6 of the 9 factors compared between the two stocks.

About Invizyne Technologies

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

About C4 Therapeutics

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.